Humacyte, Inc. (NASDAQ:HUMA) Director Brady W. Dougan Sells 1,522,500 Shares of Stock

Humacyte, Inc. (NASDAQ:HUMAGet Rating) Director Brady W. Dougan sold 1,522,500 shares of the company’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $4.00, for a total transaction of $6,090,000.00. Following the completion of the sale, the director now directly owns 18,930,004 shares in the company, valued at $75,720,016. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Humacyte Trading Down 5.6 %

Shares of Humacyte stock opened at $3.73 on Tuesday. The firm has a market capitalization of $384.22 million, a PE ratio of -24.87 and a beta of 1.04. Humacyte, Inc. has a twelve month low of $3.07 and a twelve month high of $14.57. The firm’s 50-day moving average price is $3.94 and its 200 day moving average price is $4.98. The company has a current ratio of 17.46, a quick ratio of 17.46 and a debt-to-equity ratio of 0.34.

Humacyte (NASDAQ:HUMAGet Rating) last issued its quarterly earnings results on Friday, August 12th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.03. The firm had revenue of $1.30 million for the quarter, compared to analyst estimates of $0.27 million. Humacyte had a net margin of 1,437.40% and a negative return on equity of 78.64%. On average, sell-side analysts predict that Humacyte, Inc. will post -0.84 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on HUMA shares. Piper Sandler lowered their price target on shares of Humacyte from $4.00 to $3.50 in a report on Friday, August 12th. BTIG Research lowered their price target on shares of Humacyte from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, July 18th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Humacyte by 107.3% in the 1st quarter. Vanguard Group Inc. now owns 2,422,020 shares of the company’s stock valued at $17,099,000 after acquiring an additional 1,253,788 shares during the last quarter. BlackRock Inc. raised its holdings in Humacyte by 12.6% in the 1st quarter. BlackRock Inc. now owns 1,577,919 shares of the company’s stock valued at $11,140,000 after acquiring an additional 176,846 shares during the last quarter. Prescott General Partners LLC raised its holdings in Humacyte by 681.4% in the 1st quarter. Prescott General Partners LLC now owns 625,100 shares of the company’s stock valued at $4,413,000 after acquiring an additional 545,100 shares during the last quarter. State Street Corp raised its holdings in Humacyte by 73.3% in the 2nd quarter. State Street Corp now owns 418,042 shares of the company’s stock valued at $1,342,000 after acquiring an additional 176,839 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in Humacyte by 40.6% in the 2nd quarter. Millennium Management LLC now owns 398,765 shares of the company’s stock valued at $1,280,000 after acquiring an additional 115,192 shares during the last quarter. 13.05% of the stock is owned by hedge funds and other institutional investors.

Humacyte Company Profile

(Get Rating)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).

Further Reading

Insider Buying and Selling by Quarter for Humacyte (NASDAQ:HUMA)

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.